In Curza’s Ribosomal Antibiotic Program, our focus is on developing novel antibiotics for ESKAPE pathogens or “superbugs”. ESKAPE pathogens include Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter species and Escherichia coli. Curza has designed two novel classes of antibiotics that show both selectivity and potent activity against many of the ESKAPE pathogens.
Curza’s goal is to develop novel classes of antibiotics that combat the rising epidemic of antibiotic resistance that now kills over 700,000 people every year. Our goal is also to introduce a completely novel class of antibiotics to the market to fight the alarming emergence of bacteria that have developed resistance to all existing drug classes. Currently, drug-resistant pathogens cause mortality rates approaching 50 percent in some infection types. With hospital acquired infections and drug-resistant infections around the world on the rise, new classes of antibiotics are desperately needed.